CN107406851A - 利用smad7反义寡核苷酸治疗受试者的方法和组合物 - Google Patents

利用smad7反义寡核苷酸治疗受试者的方法和组合物 Download PDF

Info

Publication number
CN107406851A
CN107406851A CN201580069041.9A CN201580069041A CN107406851A CN 107406851 A CN107406851 A CN 107406851A CN 201580069041 A CN201580069041 A CN 201580069041A CN 107406851 A CN107406851 A CN 107406851A
Authority
CN
China
Prior art keywords
smad7
day
antisense oligonucleotide
patient
polymorphic form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580069041.9A
Other languages
English (en)
Chinese (zh)
Inventor
乔瓦尼·蒙泰莱奥内
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nuo Geer Pharmaceutical Co Ltd
Original Assignee
Nuo Geer Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuo Geer Pharmaceutical Co Ltd filed Critical Nuo Geer Pharmaceutical Co Ltd
Publication of CN107406851A publication Critical patent/CN107406851A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201580069041.9A 2014-10-17 2015-10-16 利用smad7反义寡核苷酸治疗受试者的方法和组合物 Pending CN107406851A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462065598P 2014-10-17 2014-10-17
US62/065,598 2014-10-17
PCT/EP2015/074066 WO2016059239A1 (en) 2014-10-17 2015-10-16 Methods and compositions for treating a subject with a smad7 antisense oligonucleotide

Publications (1)

Publication Number Publication Date
CN107406851A true CN107406851A (zh) 2017-11-28

Family

ID=54330761

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580069041.9A Pending CN107406851A (zh) 2014-10-17 2015-10-16 利用smad7反义寡核苷酸治疗受试者的方法和组合物

Country Status (12)

Country Link
US (2) US10337004B2 (enExample)
EP (1) EP3207136A1 (enExample)
JP (1) JP2017532961A (enExample)
KR (1) KR20170069262A (enExample)
CN (1) CN107406851A (enExample)
AU (1) AU2015332624A1 (enExample)
CA (1) CA2964667A1 (enExample)
EA (1) EA201790867A1 (enExample)
IL (1) IL251717A0 (enExample)
MA (1) MA43331A (enExample)
MX (1) MX2017004973A (enExample)
WO (1) WO2016059239A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
KR101921014B1 (ko) 2008-11-13 2018-11-21 노그라 파마 리미티드 안티센스 조성물 및 그의 제조 및 사용 방법
EP2748611B1 (en) 2011-09-15 2016-11-23 Nogra Pharma Limited Methods for monitoring responsiveness to anti-smad7 therapy
ES2732252T3 (es) 2012-04-18 2019-11-21 Nogra Pharma Ltd Procedimientos para tratar diabetes y/o promover la supervivencia de los islotes pancreáticos después del trasplante
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
US10473669B2 (en) 2014-05-09 2019-11-12 Nogra Pharma Limited Methods for treating inflammatory bowel disease
MX2017004973A (es) 2014-10-17 2017-12-07 Nogra Pharma Ltd Metodos y composiciones para tratar a un sujeto con un oligonucleotido antisentido de smad7.
EP3693736A3 (en) * 2014-10-17 2020-10-14 Nogra Pharma Limited Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels
EP3420082A4 (en) 2016-02-23 2019-10-16 Celgene Alpine Investment Company II, LLC METHOD FOR THE TREATMENT OF DARM FIBROSIS USING SMAD7 INHIBITION
JP2020503327A (ja) * 2016-12-30 2020-01-30 ノグラ ファーマ リミテッド Ｓｍａｄ７アンチセンスオリゴヌクレオチドの組成物および乾癬を処置するまたは予防する方法
EP4139459A2 (en) * 2020-04-24 2023-03-01 Nogra Pharma Limited Compositions of smad7 antisense oligonucleotides (aso) and methods of using the same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087920A1 (en) * 2003-04-02 2004-10-14 Giuliani International Limited Antisense oligonucleotides (odn) against smad7 and uses in medical field thereof
CN104040349A (zh) * 2011-09-15 2014-09-10 诺格尔制药有限公司 用于监测对抗smad7疗法的反应性的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE554169T1 (de) 2001-11-02 2012-05-15 Giuliani Int Ltd Smad7-inhibitoren zur behandlung von krankheiten des zns
KR101921014B1 (ko) 2008-11-13 2018-11-21 노그라 파마 리미티드 안티센스 조성물 및 그의 제조 및 사용 방법
US9062311B2 (en) * 2009-01-26 2015-06-23 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Means and methods for modulating NOTCH3 protein expression and/or the coding region of NOTCH3; compositions and use thereof in the treatment of CADASIL
US9006198B2 (en) * 2010-02-08 2015-04-14 Isis Pharmaceuticals, Inc. Selective reduction of allelic variants
ES2732252T3 (es) 2012-04-18 2019-11-21 Nogra Pharma Ltd Procedimientos para tratar diabetes y/o promover la supervivencia de los islotes pancreáticos después del trasplante
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
RU2674147C2 (ru) 2013-03-15 2018-12-05 Ногра Фарма Лимитед Способы лечения колоректального рака
US10473669B2 (en) 2014-05-09 2019-11-12 Nogra Pharma Limited Methods for treating inflammatory bowel disease
MX2017004973A (es) 2014-10-17 2017-12-07 Nogra Pharma Ltd Metodos y composiciones para tratar a un sujeto con un oligonucleotido antisentido de smad7.
WO2015011694A2 (en) 2014-10-17 2015-01-29 Celgene Corporation Isotopologues of smad7 antisense oligonucleotides
EP3693736A3 (en) 2014-10-17 2020-10-14 Nogra Pharma Limited Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels
MA41271A (fr) 2014-12-26 2017-10-31 Celgene Alpine Invest Company Ii Llc Méthodes d'utilisation d'oligonucléotides antisens ciblant smad7
CA3000195A1 (en) 2015-09-30 2017-04-06 Celgene Alpine Investment Company Ii, Llc Tlr modulators and methods of use
JP2018531936A (ja) 2015-09-30 2018-11-01 ノグラ ファーマ リミテッド バイオマーカー発現に基づいてｓｍａｄ７アンチセンスオリゴヌクレオチドを使用する方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087920A1 (en) * 2003-04-02 2004-10-14 Giuliani International Limited Antisense oligonucleotides (odn) against smad7 and uses in medical field thereof
CN104040349A (zh) * 2011-09-15 2014-09-10 诺格尔制药有限公司 用于监测对抗smad7疗法的反应性的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
无: "无", 《NCBI REFERENCE SNP ID(RS#): RS144204026》 *

Also Published As

Publication number Publication date
US10337004B2 (en) 2019-07-02
AU2015332624A1 (en) 2017-05-04
IL251717A0 (en) 2017-06-29
EA201790867A1 (ru) 2017-08-31
MX2017004973A (es) 2017-12-07
EP3207136A1 (en) 2017-08-23
KR20170069262A (ko) 2017-06-20
JP2017532961A (ja) 2017-11-09
CA2964667A1 (en) 2016-04-21
US20170240893A1 (en) 2017-08-24
US20190338283A1 (en) 2019-11-07
MA43331A (fr) 2017-08-23
WO2016059239A1 (en) 2016-04-21

Similar Documents

Publication Publication Date Title
CN107406851A (zh) 利用smad7反义寡核苷酸治疗受试者的方法和组合物
US20200032264A1 (en) Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels
CN107530431B (zh) 生物标志物
Bogaert et al. Differential mucosal expression of Th17-related genes between the inflamed colon and ileum of patients with inflammatory bowel disease
JP2017515896A (ja) 炎症性腸疾患の処置の方法
US20210207143A1 (en) Methods of Treating Celiac Disease Using SMAD7 Inhibition
EP3355896A2 (en) Methods of using smad7 antisense oligonucleotides based on biomarker expression
AU2016300175A1 (en) FGFR expression and susceptibility to an FGFR inhibitor
CN113645991A (zh) 靶向il18r1的、用于治疗炎性疾病的方法、系统和试剂盒
EP4256086A1 (en) Methods and systems of stratifying inflammatory disease patients
CA3180632A1 (en) Methods and systems for measuring post-operative disease recurrence
WO2020079581A1 (en) Tumor mutation burden alone or in combination with immune markers as biomarkers for predicting response to targeted therapy
CA2972076A1 (en) Combination of raf inhibitors and aurora kinase inhibitors
US20220364184A1 (en) Compositions and methods for treatment of a poor prognosis subtype of colorectal cancer
US20140378388A1 (en) Treatment of uterine leiomyomata
Anaparti et al. Whole blood targeted bisulfite sequencing validates differential methylation in C6ORF10 gene of patients with rheumatoid arthritis
JP2012080777A (ja) ネフローゼ症候群の検査方法、並びにネフローゼ症候群の予防又は治療薬およびそのスクリーニング方法
JP2025042914A (ja) もやもや病の発症を予測する方法
JP4869834B2 (ja) 抗ヒトＴＮＦαキメラ抗体を含有する薬剤に対する副作用に関連する多型、およびその利用
HK40059533A (en) Methods, systems, and kits for treating inflammatory disease targeting il18r1
WO2020165370A1 (en) Methods and compositions for selecting a cancer treatment in a subject suffering from cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20171128

WD01 Invention patent application deemed withdrawn after publication